Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors

Mariangela Librizzi, James E. Bradner, Robin S. B. Williams, Peter Coxhead, Minghua Wang, Ronald M. Paranal, Mariangela Librizzi, Alexandra Zuckermann, John Spencer, Hiren Patel, Irina Chuckowree, Matthew Guille

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)

Abstract

Fragments based on the VEGFR2i Semaxanib (SU5416, (vascular endothelial growth factor receptor-2 inhibitor) and the HDACi (histone deacetylase inhibitor) SAHA (suberanilohydroxamic acid) have been merged to form a range of low molecular weight dual action hybrids. Vindication of this approach is provided by SAR, docking studies, in vitro cancer cell line and biochemical enzyme inhibition data as well as in vivo Xenopus data for the lead molecule (Z)-N1-(3-((1H-pyrrol-2-yl) methylene)-2-oxoindolin-5-yl)N8- hydroxyoctanediamide 6
Original languageEnglish
Pages (from-to)1829-1833
Number of pages5
JournalMedChemComm
Volume5
Publication statusPublished - 2014

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry

Fingerprint Dive into the research topics of 'Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors'. Together they form a unique fingerprint.

Cite this